| Literature DB >> 20541246 |
Leena Kainulainen1, Tytti Vuorinen, Kaisu Rantakokko-Jalava, Riikka Osterback, Olli Ruuskanen.
Abstract
BACKGROUND: The occurrence of respiratory tract viral infections in patients with primary hypogammaglobulinemia has not been studied.Entities:
Mesh:
Year: 2010 PMID: 20541246 PMCID: PMC7112312 DOI: 10.1016/j.jaci.2010.04.016
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793
Patient demographics
| Patient no. | Sex | Age (y) | Diagnosis | Age at diagnosis (y) | Serum IgG/IgA/IgM level at diagnosis (g/L) | Through serum IgG level (g/L) | Replacement therapy | Pulmonary complications |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 79 | CVID | 59 | 2.5/<0.1/0.1 | 5.5 | IVIG | Bronchiectasis, fibrosis |
| 2 | M | 32 | XLA | 1 | 1/<0.1/0.1 | 9 | IVIG | Bronchiectasis |
| 3 | M | 36 | CVID | 32 | 3.2/>0.2/<0.2 | 5.5 | IVIG | Bronchiectasis, noduli |
| 4 | F | 45 | CVID | 33 | 2.5/<0.2/0.3 | 5.4 | IVIG | Bronchiectasis |
| 5 | M | 54 | CVID | 29 | 1.5/<0.2/<0.2 | 6.5 | IVIG | Fibrosis, mild bronchiectasis |
| 6 | M | 39 | CVID | 24 | 4.0/<0.2/0.4 | 6.0 | IVIG | Bronchiectasis, noduli |
| 7 | M | 42 | XLA | 1 | 1/<0.2/0.2 | 7.6 | IVIG/SCIG | Bronchiectasis |
| 8 | M | 57 | CVID | 22 | 2.5/<0.2/<0.2 | 7.0 | IVIG | Bronchiectasis |
| 9 | F | 49 | CVID | 33 | 2.3/<0.2/<0.2 | 6.0 | IVIG | Bronchiectasis |
| 10 | M | 51 | CVID | 48 | <0.5/<0.2/<0.2 | 6.2 | IVIG | Bronchiectasis, noduli |
| 11 | M | 46 | CVID | 18 | 2.2/<0.2/<0.2 | 6.5 | IVIG | Bronchiectasis |
| 12 | M | 68 | CVID | 24 | 1.7/<0.2/<0.2 | 6.0 | IVIG | Bronchiectasis |
F, Female; IVIG, intravenous immunoglobulin; M, male; SCIG, subcutaneous immunoglobulin.
Bacteria and viruses in sputum and nasal swab samples at the time of acute infection and at control or follow-up visits
| Sputum at acute infection | Nasal swab at acute infection | Sputum at control | Nasal swab at control | |
|---|---|---|---|---|
| Single bacteria | ||||
| | 10 | 8 | 0 | 0 |
| | 7 | 3 | 1 | 0 |
| | 2 | 6 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| Two bacteria | ||||
| | 1 | 0 | 1 | 0 |
| | 0 | 2 | 0 | 0 |
| Bacterial and viral coinfection | ||||
| | 2 | 1 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 3 | 1 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 3 | 3 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| | 1 | 0 | 0 | 0 |
| Single virus | ||||
| Rhinovirus | 6 | 14 | 7 | 24 |
| Coronavirus | 4 | NS | 1 | NS |
| Adenovirus | 1 | 0 | 2 | 0 |
| RSV | 1 | 0 | 0 | 0 |
| Enterovirus | 0 | 0 | 2 | 0 |
| Two or 3 viruses | ||||
| Rhinovirus + adenovirus | 2 | 0 | 1 | 0 |
| Rhinovirus + enterovirus + metapneumovirus | 1 | 0 | 1 | 0 |
| Rhinovirus + metapneumovirus + coronavirus | 1 | 0 | 0 | 0 |
| Enterovirus + metapneumovirus | 1 | 0 | 1 | 0 |
| Metapneumovirus + coronavirus | 1 | 0 | 0 | 0 |
| Adenovirus + parainfluenza type 2 virus | 0 | 0 | 1 | 0 |
NS, Not studied.
Fig 1Symptoms, infections, microbiological findings, antibiotic treatments, and immunoglobulin infusions over 12 months in 12 patients.
Fig 2Phylogenetic tree of rhinovirus partial 5′ NCR sequences of nasal and sputum specimens of a patient with XLA for a 5-month period and rhinovirus prototypes HRV4, HRV21, and HRV89 (GenBank accession numbers DQ473490, FJ445121, and FJ445184). Scale bars indicate nucleotide substitutions per position.